Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial. | 2012-03 |
|
| Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. | 2003-07-15 |
|
| IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis. | 2000-07 |
|
| Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. | 1999-05 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10858334
The minimal inhibitory concentrations (MICs) of iseganan (IB-367) ranged from 0.13 to 64 microgram/ml for gram-positive bacteria (Streptococcus mitis, Streptococcus sanguis, Streptococcus salivarius, and Staphylococcus aureus) and from 0.06 to 8 microgram/ml for gram-negative species (Klebsiella, Escherichia, and Pseudomonas). IB-367 exhibited rapid, microbicidal activity against both log- and stationary-phase cultures of methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. At concentrations near the MICs for these two organisms (4 and 2 microgram/ml, respectively), IB-367 reduced viability by more than 3 logs in less than 16 min. Similarly, IB-367 effected a 4-log reduction of the endogenous microflora in pooled human saliva within 2 min at 250 microgram/ml, a concentration readily attained by local delivery.
| Substance Class |
Protein
Created
by
admin
on
Edited
Mon Mar 31 21:26:55 GMT 2025
by
admin
on
Mon Mar 31 21:26:55 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
HFF9H8LHP0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
256475-21-5
Created by
admin on Mon Mar 31 21:26:55 GMT 2025 , Edited by admin on Mon Mar 31 21:26:55 GMT 2025
|
PRIMARY | |||
|
m6420
Created by
admin on Mon Mar 31 21:26:55 GMT 2025 , Edited by admin on Mon Mar 31 21:26:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
HFF9H8LHP0
Created by
admin on Mon Mar 31 21:26:55 GMT 2025 , Edited by admin on Mon Mar 31 21:26:55 GMT 2025
|
PRIMARY | |||
|
70691416
Created by
admin on Mon Mar 31 21:26:55 GMT 2025 , Edited by admin on Mon Mar 31 21:26:55 GMT 2025
|
PRIMARY | |||
|
DTXSID60180337
Created by
admin on Mon Mar 31 21:26:55 GMT 2025 , Edited by admin on Mon Mar 31 21:26:55 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_5 | 1_14 |
| 1_7 | 1_12 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
STARTING MATERIAL -> INGREDIENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
Agent Modifications
| Modification Process | Modification Role | Modification Type | Amount | Fragment Name | Fragment ID |
|---|---|---|---|---|---|
| AMINE SALT FORMATION | CHEMICAL |
|
Hydrochloric Acid | QTT17582CB |
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| C-TERMINAL AMIDE | [1_17] | R | ARGININAMIDE, L- | 29626ZE0WY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:CALCULATED ANHYDROUS | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|